Title:
METHOD FOR EVALUATING AND METHOD FOR MONITORING THERAPEUTIC EFFECT IN CRITICAL LIMB ISCHEMIA PATIENT AFTER ANGIOGENIC THERAPY, REAGENT FOR EVALUATING THERAPEUTIC EFFECT, AND DEVICE AND COMPUTER PROGRAM FOR EVALUATING THERAPEUTIC EFFECT
Document Type and Number:
WIPO Patent Application WO/2017/204244
Kind Code:
A1
Abstract:
Provided is a method whereby therapeutic effect in a critical limb ischemia patient after angiogenic therapy can be objectively evaluated with minimal patient burden. The problem addressed by the present invention is solved by a method for evaluating therapeutic effect in a peripheral arterial occlusive disease patient after angiogenic therapy, the evaluation method including a measurement step for measuring the concentration of VEGF-A165b in patient blood and an evaluation step for evaluating therapeutic effect using a change over time in the measured concentration of VEGF-A165b as an index.
More Like This:
Inventors:
KIKUCHI RYOSUKE (JP)
KONDO KAZUHISA (JP)
MUROHARA TOYOAKI (JP)
KONDO KAZUHISA (JP)
MUROHARA TOYOAKI (JP)
Application Number:
PCT/JP2017/019338
Publication Date:
November 30, 2017
Filing Date:
May 24, 2017
Export Citation:
Assignee:
UNIV NAGOYA NAT UNIV CORP (JP)
International Classes:
G01N33/68
Foreign References:
| JP2012509306A | 2012-04-19 | |||
| JP2010520922A | 2010-06-17 |
Other References:
KIKUCHI, R ET AL.: "An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease", NAT MED., vol. 20, no. 12, December 2014 (2014-12-01), pages 1464 - 1471, XP055442124, Retrieved from the Internet [retrieved on 20170620]
CARTER, JG ET AL.: "The carboxyl terminus of VEGF-A is a potential target for anti- angiogenic therapy", ANGIOGENESIS, vol. 18, no. 1, January 2015 (2015-01-01), pages 23 - 30, XP035416196
RYOSUKE KIKUCHI: "Ko Kekkan Shinsei Inshi to shiteno VEGF-A = [VEGF-A as an anti-angiogenic factor]", CELL TECHNOLOGY, vol. 35, no. 1, 22 December 2015 (2015-12-22), pages 48 - 50, XP009515030
FUJIMOTO, H ET AL.: "Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease", CLIN CHEM., vol. 59, no. 9, September 2013 (2013-09-01), pages 1330 - 1337, XP055442128
See also references of EP 3467506A4
CARTER, JG ET AL.: "The carboxyl terminus of VEGF-A is a potential target for anti- angiogenic therapy", ANGIOGENESIS, vol. 18, no. 1, January 2015 (2015-01-01), pages 23 - 30, XP035416196
RYOSUKE KIKUCHI: "Ko Kekkan Shinsei Inshi to shiteno VEGF-A = [VEGF-A as an anti-angiogenic factor]", CELL TECHNOLOGY, vol. 35, no. 1, 22 December 2015 (2015-12-22), pages 48 - 50, XP009515030
FUJIMOTO, H ET AL.: "Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease", CLIN CHEM., vol. 59, no. 9, September 2013 (2013-09-01), pages 1330 - 1337, XP055442128
See also references of EP 3467506A4
Attorney, Agent or Firm:
MATSUMOTO Seiji (JP)
Download PDF:
Previous Patent: THERMOPLASTIC RESIN COMPOSITION, MOLDED BODY, FILM, AND LAMINATE
Next Patent: BOARD ASSEMBLY AND ELECTRONIC ENDOSCOPE SYSTEM
Next Patent: BOARD ASSEMBLY AND ELECTRONIC ENDOSCOPE SYSTEM